Shattuck Labs is a clinical-stage biotechnology company advancing novel biologic medicines for inflammatory and immune-mediated diseases. Its lead program, SL-325, is a potentially first-in-class antibody that targets the DR3 receptor to more effectively block pro-inflammatory signaling in conditions like inflammatory bowel disease.

IPO in October 2020 (NASDAQ: STTK)